Bavarian-CEO: ”Yellow fever, hepatitis, you name it”
Bavarian Nordic’s development contract with the US authorities gives the CEO of the company hope that its vaccine technology can be expanded to diseases with a greater commercial potential.
af LEONORA BECK
Earlier today Bavarian Nordic announced it had signed a contract with the US government, the aim of which it is to examine if the company’s vaccine technology can be used against other diseases. According to CEO Anders Hedegaard the deal is a direct consequence of a year-long collaboration with the Americans concerning the company’s technology.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Bavarian strikes a new deal with the US government
For abonnenter
